Robert Bertolini - Bristol Myers Independent Director

BMY Stock  USD 53.25  0.70  1.33%   

Director

Mr. Robert J. Bertolini, CPA., is Independent Director of the Company since 2017.
Age 58
Tenure 7 years
Address Route 206 & Province Line Road, Princeton, NJ, United States, 08543
Phone609 252 4621
Webhttps://www.bms.com
Bertolini served as President and Chief Financial Officer of Bausch & Lomb Incorporated from February 2013 until August 2013 . Previously, he served as Executive Vice President and Chief Financial Officer at ScheringPlough Corporation from November 2003 until November 2009 with responsibility for tax, accounting and financial asset management. Prior to joining ScheringPlough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice.

Bristol Myers Management Efficiency

The company has Return on Asset of 0.0563 % which means that on every $100 spent on assets, it made $0.0563 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2653 %, implying that it generated $0.2653 on every 100 dollars invested. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.29 in 2024. Return On Assets is likely to rise to 0.14 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.
The company has 41.46 B in debt with debt to equity (D/E) ratio of 1.32, which is OK given its current industry classification. Bristol-Myers Squibb has a current ratio of 1.39, which is typical for the industry and considered as normal. Debt can assist Bristol Myers until it has trouble settling it off, either with new capital or with free cash flow. So, Bristol Myers' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bristol-Myers Squibb sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bristol to invest in growth at high rates of return. When we think about Bristol Myers' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Ettore Artioli23Andme Holding Co
N/A
Mala AnandAgilent Technologies
53
Dow WilsonAgilent Technologies
61
AnnChristine Hvittfeldt23Andme Holding Co
49
James DalyMadrigal Pharmaceuticals
N/A
Scott MorensteinMadrigal Pharmaceuticals
38
David BerrySeres Therapeutics
37
Robert WilsonMadrigal Pharmaceuticals
75
Carina Olofsson23Andme Holding Co
42
Kenneth BateMadrigal Pharmaceuticals
67
Charles McDermottEquillium
45
Giuseppe Lettieri23Andme Holding Co
33
Paul ClarkAgilent Technologies
72
Robert HerboldAgilent Technologies
74
Staffan Gavel23Andme Holding Co
67
Johannes Tiden23Andme Holding Co
34
Vincenzo Capizzi23Andme Holding Co
N/A
Daniel PodolskyAgilent Technologies
67
William ReardonMadrigal Pharmaceuticals
68
Hans BishopAgilent Technologies
56
George ScangosAgilent Technologies
72
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 32200 people. Bristol Myers Squibb (BMY) is traded on New York Stock Exchange in USA. It is located in Route 206 & Province Line Road, Princeton, NJ, United States, 08543 and employs 34,100 people. Bristol Myers is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Bristol-Myers Squibb Leadership Team

Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jitendra Tyagi, Head India
Togo West, Independent Director
Adam Dubow, Senior Vice President, Chief Compliance Officer and Ethics Officer, Member of the Leadership Team
Michael Bonney, Independent Director
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Catherine Owen, Senior Markets
Jose Baselga, Independent Director
Michael Grobstein, Independent Director
Phyllis Yale, Independent Director
John Elicker, Senior Vice President - Corporate Affairs and Investor Relations
BCH BM, Ex Devel
Karen Santiago, Senior Vice President, Corporate Controller
Rupert Vessey, Executive Vice President - Research and Early Development, Member of the Leadership Team
Giovanni Caforio, Chairman of the Board, Chief Executive Officer
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Nadim Ahmed, Executive Vice President and President - Hematology
Joseph Caldarella, Senior Vice President Corporate Controller
Murdo Gordon, Executive Vice President Chief Commercial Officer
Cari Gallman, VP Officer
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee
Matthew Emmens, Independent Director
Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Sandra Leung, Executive Vice President, General Counsel, Member of the Leadership Team
Ahn Poole, Executive Officer
Paul Autenried, Executive Vice President, Chief Information Officer, Member of the Leadership Team
Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team
Tim Power, Vice President of Investor Relations
Giovanni MD, Executive Board
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President, Head of Strategy & Business Development
Greg Meyers, Executive Vice President Chief Digital and Technology Officer, Member of the Leadership Team
Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership Team
Peter Arduini, Independent Director
Michelle Weese, Executive Vice President - Corporate Affairs, Member of the Leadership Team
Joseph Eiden, Head Affairs
Elizabeth Mily, Executive Vice President - Strategy and Business Development, Member of the Leadership Team
Ann Powell, Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team
Karen Vousden, Independent Director
Paula Price, Independent Director
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business Operations
Gerald Storch, Independent Director
Sandra Esq, Executive Counsel
Louis Schmukler, Executive Vice President, President - Global Product Development and Supply, Member of the Leadership Team
Christopher Boerner, Executive Vice President and Chief Commercial Officer, Member of the Leadership Team
Kimberly Jablonski, Chief Officer
David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership Team
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Vicki Sato, Lead Independent Director
Manuel Medina, Independent Director
Julia Haller, Independent Director
Laurie Glimcher, Independent Director
Joseph Eid, Senior Vice President and Head of Global Medical Affairs, Member of the Leadership Team
Thomas Lynch, Chief Scientific Officer, Executive Vice President
Derica Rice, Independent Director
Lewis Campbell, Independent Director
Dinesh Paliwal, Independent Director
Theodore Samuels, Lead Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Timothy Power, VP Relations
Adam Lenkowsky, Chief VP
Samit MD, Executive Development

Bristol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

  0.69MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Bristol Stock

  0.7MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.6MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.56KA Kineta Inc Report 29th of March 2024 PairCorr
  0.56VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.